<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39438198</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-499X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Trends in molecular medicine</Title><ISOAbbreviation>Trends Mol Med</ISOAbbreviation></Journal><ArticleTitle>Assessment of the therapeutic potential of salubrinal for ME/CFS and long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1471-4914(24)00268-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmed.2024.10.001</ELocationID><Abstract><AbstractText>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating condition with no cure that shares commonality with long-COVID. This review examines current understanding of long-COVID symptoms, characteristics of the affected population, the connection with ME/CFS, and the potential for salubrinal, an agent known for its influence on cellular stress pathways, to mitigate these disorders It also describes the historical development and mechanism of action of salubrinal, to mitigate endoplasmic reticulum (ER)/cellular stress responses, that could potentially contribute to symptom improvement in both ME/CFS and long-COVID patients. Further research and clinical trials are warranted to advance our understanding of the potential role of salubrinal in improving the quality of life for individuals with long-COVID-related ME/CFS symptoms as well as ME/CFS patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Warrayat</LastName><ForeName>Aseel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Ayah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waked</LastName><ForeName>Joulin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tocci</LastName><ForeName>Darcy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Speth</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA; Department of Pharmacology and Physiology, School of Medicine, Georgetown University, Washington, DC 20007, USA. Electronic address: rs1251@nova.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Mol Med</MedlineTA><NlmUniqueID>100966035</NlmUniqueID><ISSNLinking>1471-4914</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">endoplasmic reticulum/cellular stress pathways</Keyword><Keyword MajorTopicYN="N">eukaryotic initiation factor 2&#x3b1; (eIF2&#x3b1;)</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</Keyword><Keyword MajorTopicYN="N">salubrinal</Keyword></KeywordList><CoiStatement>Declaration of interests The authors report no conflicts of interest that could affect the objectivity of the information presented in this review.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438198</ArticleId><ArticleId IdType="doi">10.1016/j.molmed.2024.10.001</ArticleId><ArticleId IdType="pii">S1471-4914(24)00268-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>